Finally, a dual therapy targeting both GLP-1 and GIP incretin receptors, proposed as improved candidates for T2D treatment, has shown to ameliorate memory impairment, Aβ deposition, glial reactivity and expression of synaptic marker PSD95 in 10-month-old APP/PS1 mice, potentially due to the rescue of proteostatic functions associated to the enhancement of autophagy and decreased ERS response (Panagaki et al., 2018). Here, GCG is linked to type 2 diabetes mellitus.